Law groups, professors lash out against Thermo Fisher in suit over the 'immortal cells' of Henrietta Lacks

Nicole DeFeudis

Editor

It’s been decades since medical researchers at Johns Hopkins unethically took tissue samples from Henrietta Lacks and used them to create the world’s first known …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Law groups, professors lash out against Thermo Fisher in suit over the 'immortal cells' of Henrietta Lacks

Nicole DeFeudis

Editor

Sign up to read this article for free.

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Law groups, pro­fes­sors lash out against Ther­mo Fish­er in suit over the 'im­mor­tal cell­s' of Hen­ri­et­ta Lacks

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Law groups, professors lash out against Thermo Fisher in suit over the 'immortal cells' of Henrietta Lacks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway